Cellectar Biosciences, Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022. Cellectar is a clinical-stage biopharmaceutical company developing cancer therapies using its phospholipid drug conjugate (PDC) platform. The filing reports no product revenue; results primarily reflect research and development and corporate operating costs.
Financial performance and liquidity
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $3.89 million | $4.63 million; down 16% |
| General and administrative expense | $2.25 million | $1.73 million; up 31% |
| Net loss | $6.14 million | $6.36 million |
| Basic and diluted loss per share | $0.10 | $0.13 |
| Cash used in operating activities | $5.04 million | $4.75 million |
| Cash and cash equivalents | $30.63 million at March 31, 2022 | $35.70 million at December 31, 2021; $53.63 million at March 31, 2021 |
R&D expense fell mainly because clinical project costs declined by about $1.54 million, partly offset by higher manufacturing, personnel, and preclinical costs. G&A increased by about $527,000, primarily due to professional fees, personnel costs, stock compensation, and travel. Operating margin is not meaningful for this pre-revenue company. No borrowings or interest-bearing debt are reported; lease liabilities totaled approximately $269,000, including current and long-term portions.
At quarter-end, current assets were $31.39 million and current liabilities were $4.65 million. Stockholders’ equity was $27.21 million and accumulated deficit was $157.04 million. Cash decreased by $5.07 million during the quarter; the company had no financing cash inflow in Q1 2022.
Business developments, outlook, and risks
- Management said quarter-end cash should fund basic budgeted operations for at least 12 months from the filing date. Continuing operations beyond that depend on additional financing through equity or debt, a strategic transaction, or other sources; there is no assurance funding will be obtained. The company expects operating losses to continue.
- The lead candidate, iopofosine (CLR 131), is being evaluated in several studies, including the pivotal CLOVER-WaM study in relapsed or refractory Waldenström’s macroglobulinemia (WM). COVID-19-related site resourcing and patient concerns materially delayed recruitment and enrollment. In April 2022, after quarter-end, the independent monitoring committee recommended continuing CLOVER-WaM as planned following its futility/efficacy assessment.
- Management described clinical and manufacturing timelines as uncertain, including because of COVID-19 impacts on trial sites, suppliers, and third parties. Iopofosine relies on a sole supplier. The filing also identifies the company’s ability to raise capital and maintain Nasdaq listing standards as risks.
- Reported safety concerns across iopofosine studies include cytopenias and fatigue; infections have resulted in fatalities in treated patients. Trial results and safety observations are preliminary and do not assure future outcomes or regulatory approval.
- The company is pursuing a lawsuit alleging that a former director/executive and a former employee/consultant diverted intellectual property. It seeks damages and injunctive relief; the filing says the disputed IP does not directly affect current iopofosine or other clinical pipeline studies but may have potential future value.
- Management reported effective disclosure controls and no significant changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether cash burn and updated operating plans remain consistent with management’s stated minimum 12-month runway, and what financing alternatives are available.
- Enrollment progress, timing, and outcome milestones for CLOVER-WaM and other iopofosine studies, including the effect of continuing site and patient recruitment challenges.
- Current manufacturing and supply arrangements for iopofosine, including exposure to its sole supplier.
- Clinical safety and efficacy data, adverse-event developments, and regulatory requirements for each program.
- Potential dilution from future equity financing and outstanding warrants and stock options; the filing lists 15.63 million warrants outstanding at March 31, 2022.
- Developments and potential financial or intellectual-property consequences of the pending lawsuit.